SELLAS Life Sciences Announces Poster Presentation at the Society of Hematologic Oncology (SOHO) Annual Meeting

Rhea-AI Summary

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) announced a poster presentation at the Tenth Annual Meeting of the Society of Hematologic Oncology on September 28, 2022, showcasing preclinical pharmacokinetic profiles of GFH009. This selective CDK9 inhibitor, under development for various cancer types, demonstrates an important step in its clinical development.

The presentation will be led by Dragan Cicic, MD, and highlights two GFH009 formulations with distinct pH levels. SELLAS aims to advance therapeutic options targeting hematologic malignancies and solid tumors.

Positive

• Upcoming poster presentation on GFH009 at a notable oncology meeting, potentially increasing visibility and interest.
• GFH009 is a selective CDK9 inhibitor, indicating innovative approach in cancer treatment.
• Potential for GFH009 to address a wide range of cancer types, enhancing the company's developmental pipeline.

Negative

• None.

NEW YORK, Sept. 22, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced its upcoming poster presentation related to its highly selective CDK9 inhibitor, GFH009, at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) being held on September 28 through October 1, 2022, in Houston, Texas and virtually.

The poster presentation characterizes the preclinical pharmacokinetic (PK) profiles of two different formulations of GFH009 maleate, pH 4.5 and pH 6.0.

Additional presentation details can be found below:

Title: “Pharmacokinetics and Bioequivalence of Two Formulations of GFH009 Maleate Injection in Sprague Dawley Rats”

Abstract #: AML-259

Date/Time: Wednesday, September 28, 2022 at 6:05 PM ET

Presenter: Dragan Cicic, MD, Senior Vice President, Clinical Development, of SELLAS

About SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing GFH009, a small molecule, highly selective CDK9 inhibitor, which is licensed from GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of Greater China.

For more information on SELLAS, please visit www.sellaslifesciences.com.

Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as “plan,” “expect,” “anticipate,” “may,” “might,” “will,” “should,” “project,” “believe,” “estimate,” “predict,” “potential,” “intend,” or “continue” and other words or terms of similar meaning. These statements include, without limitation, statements related to preclinical data for GFH009, plans for further development of GFH009, and the potential for GFH009 as a drug development candidate. These forward-looking statements are based on current plans, objectives, estimates, expectations and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with the COVID-19 pandemic and its impact on the Company’s clinical plans and business strategy, risks and uncertainties associated with oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption “Risk Factors” in SELLAS’ Annual Report on Form 10-K filed on March 31, 2022 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS’ forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.

Investor Contact
Allison Soss
KCSA Strategic Communications
Email: SELLAS@kcsa.com
Phone: 212.896.1267

Media Contacts
Raquel Cona / Michaela Fawcett
KCSA Strategic Communications
Email: SELLAS@kcsa.com
Phone: 212.896.1276

FAQ

What is the significance of the GFH009 presentation at SOHO 2022 for SELLAS (SLS)?

The presentation highlights the pharmacokinetic profiles of GFH009, a key step in its clinical development for cancer treatment, which could attract interest from investors and the medical community.

When will SELLAS present information about GFH009?

SELLAS will present details about GFH009 on September 28, 2022, at 6:05 PM ET during the SOHO Annual Meeting.

What is the focus of SELLAS Life Sciences Group (SLS)?

SELLAS focuses on developing novel cancer therapies, with its lead candidate being the GFH009 CDK9 inhibitor, aimed at various cancer indications.

Who will present SELLAS's research on GFH009?

Dragan Cicic, MD, Senior Vice President of Clinical Development at SELLAS, will present the research findings.